Dailypharm Live Search Close

The cobas SARS-CoV-2 & Influenza A/B Test was approved

By | translator Choi HeeYoung

21.05.06 10:48:02

°¡³ª´Ù¶ó 0
Extend the cycle of workforce intervention to improve medical staff convenience

Clinical sensitivity & specification are identified at least 97%


Roche Diagnostics Korea announced on the 6th that it has obtained permission from the MFDS to "cobas SARS-CoV-2 & Fluenza A/B," which can diagnose COVID-19 and flu at the same time.

The cobas¢ç SARS-CoV-2 & Influenza A/B Test is a multiplex reverse transcription polymerase chain reaction (RT-PCR) assay intended for simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus in nasal or nasopharyngeal swab samples collected from individuals suspected of a respiratory viral infection consistent with COVID-19 by their healthcare provider.

It is based on automated molecular diagnostic equipment 'covas 6800' and 'covas 8800', and can procee

(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)